Related Experiment Video
Updated: Sep 2, 2025
A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
Published on: September 23, 2014
SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors
David Dum1, Daniela Kromm1, Maximilian Lennartz1
1From the Institute of Pathology (Dum, Kromm, Lennartz, Büscheck, Luebke, Burandt, Menz, Kluth, Hube-Magg, Hinsch, Höflmayer, Weidemann, Fraune, Möller, Lebok, Sauter, Simon, Uhlig, Wilczak, Minner, Bernreuther, Marx, Steurer, Jacobsen, Clauditz, T Krech), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Special AT-rich sequence-binding protein 2 (SATB2) is a marker in various cancers. Strong SATB2 expression suggests colorectal origin, while weak expression indicates tumor progression and poorer prognosis in colorectal and kidney cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Diagnostics
Background:
- Special AT-rich sequence-binding protein 2 (SATB2) plays a role in chromatin regulation and transcription.
- SATB2 immunostaining is a recognized marker for colorectal adenocarcinoma and osteosarcoma.
Purpose of the Study:
- To comprehensively evaluate the diagnostic utility of SATB2 analysis across a wide spectrum of human tumors.
- To investigate the association between SATB2 expression and clinicopathologic features in various cancers.
Main Methods:
- Analysis of SATB2 expression using tissue microarrays from 15,012 samples representing 120 tumor types and 76 normal tissues.
- Correlation of SATB2 positivity with tumor type, grade, stage, and patient survival outcomes.
Main Results:
- SATB2 positivity was observed in 74% of 120 tumor types.
- Frequent SATB2 expression was noted in colorectal adenomas, adenocarcinomas, neuroendocrine neoplasms, Merkel cell carcinoma, osteosarcomas, and papillary renal cell carcinoma (RCC).
- Weak SATB2 expression correlated with advanced tumor stage, metastasis, and poorer prognosis in colorectal and kidney cancers.
Conclusions:
- Strong SATB2 expression is indicative of a colorectal origin in adenocarcinomas and neuroendocrine neoplasms.
- Weak SATB2 expression serves as a prognostic marker for tumor progression and adverse outcomes in colorectal and kidney cancers.
